There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inmune Bio Inc (INMB) and Vaxart Inc (VXRT) with bullish sentiments.
Inmune Bio Inc (INMB)
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage with a Buy rating on Inmune Bio Inc today and set a price target of $11.50. The company’s shares closed last Monday at $5.94, close to its 52-week low of $5.06.
Ramakanth wrote:
“We are initiating coverage of INMB with Buy rating and a 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -11.6% and a 27.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.
Inmune Bio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $12.25, a 101.1% upside from current levels. In a report issued on August 13, Maxim Group also maintained a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
Vaxart Inc (VXRT)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Vaxart Inc today and set a price target of $2. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.55.
Bernardino said:
“Our $2 PT was derived by using a 17% weighted- average cost of capital for Vaxart shares to discount free cash flows from royalty payments to Vaxart from annual sales of the company’s norovirus and seasonal influenza vaccines, dividing them by our projected number of shares for each year to account for the effects.”
According to TipRanks.com, Bernardino ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.6% and a 29.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, Seelos Therapeutics Inc, and ENDRA Life Sciences Inc.
Currently, the analyst consensus on Vaxart Inc is a Moderate Buy with an average price target of $4, representing a 509.0% upside. In a report issued on August 15, Brookline Capital Markets also initiated coverage with a Buy rating on the stock with a $6 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
